The impact of drug vintage on patient survival: A patient-level analysis using quebec's provincial health plan data

Value in Health

Volumn 12, Issue 6, 2009, Pages 847-856

  Lichtenberg, Frank R ^a,b   Grootendorst, Paul ^c,d   Van Audenrode, Marc ^e   Latremouille Viau, Dominick ^e   Lefebvre, Patrick ^e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e GROUPE D ANALYSE   (Canada)

Author keywords

Canada; Drug innovation; Longevity; Pharmaceuticals; Survival

Indexed keywords

ANTIASTHMATIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ATENOLOL; CALCIUM; CLONAZEPAM; COLECALCIFEROL; CONJUGATED ESTROGEN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL MALEATE; ESTRADIOL; FLURAZEPAM; FUROSEMIDE; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; LORAZEPAM; MEDROXYPROGESTERONE ACETATE; METOPROLOL TARTRATE; NIFEDIPINE; OMEPRAZOLE; OXAZEPAM; PARACETAMOL; PROPRANOLOL; SALBUTAMOL; TIMOLOL; UNINDEXED DRUG;

AGED; ARTICLE; ASTHMA; CANADA; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; COMORBIDITY; DRUG CLASSIFICATION; DRUG COST; DRUG INNOVATION; DRUG MARKETING; DRUG STORAGE; DRUG USE; DRUG VINTAGE; FEMALE; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNATIONAL CLASSIFICATION OF DISEASES; LIFE EXPECTANCY; LONGEVITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; MUSCULOSKELETAL DISEASE; NEOPLASM; PATIENT CODING; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; STATISTICAL MODEL; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COMORBIDITY; DATABASES, FACTUAL; DRUG INDUSTRY; FEMALE; HUMANS; LONGEVITY; MALE; NATIONAL HEALTH PROGRAMS; ORGANIZATIONAL INNOVATION; PRESCRIPTION DRUGS; PROPORTIONAL HAZARDS MODELS; QUEBEC; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 67651207771     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00532.x     Document Type: Article

References (18)

1. Patented Medicine Prices Review Board. Annual report 2006. Available from: http://www.pmprb-cepmb.gc.ca/english/view.asp?x=903&all=true [Accessed May 27, 2008 MP, Tully P, St-Arnaud J. Life expectancy. Health Rep 2005 17 : 43 7.
2. Han D, Wang EC. The value of medicines in Canada. Can J Clin Pharmacol 2005 12 : e10 21.
3. Williams R, Marion J. Are drugs too expensive in Canada? No. Can Fam Physician 2006 52 : 573 6.
4. Lichtenberg FR. Pharmaceutical innovation and U.S. cancer survival, 1992-2003: evidence from linked SEER-MEDSTAT data. Forum Health Economics Policy 2007 10 (1 Article 1. Available from: http://www.bepress.com/fhep/10/1/1/ [Accessed May 27, 2008 HE, Krailo MD, Tarbell NT, et al. Addition of ifosfamid and etoposide to standard chemiotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003 348 : 694 701.
5. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005 352 : 2696 704.
6. Lichtenberg FR. The impact of increased utilization of HIV drugs on longevity and medical expenditure: an assessment based on aggregate U.S. time-series data. Expert Rev Pharmacoeconomics Outcomes Res 2006 6 : 425 36.
7. Lichtenberg FR. The effect of new drug approvals on HIV mortality in the US, 1987-1998. Econ Hum Biol 2003 1 : 259 66.
8. Cutler DM, Deaton A, Lleras-Muney A. The determinants of mortality. J Econ Perspect 2006 3 : 97 120.
9. Cutler DM, Long G, Berndt ER. The value of antihypertensive drugs: a perspective on medical innovation. Health Aff 2007 26 : 97 110.
10. Lichtenberg FR. Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. Health Econ 2008 July 15 [Epub ahead of print PY, Ouellette P, Petit P. Do drugs reduce utilization of other healthcare resources? Pharmacoeconomics 2007 25 : 209 21.
11. Lichtenberg FR. The impact of new drugs on U.S. longevity and medical expenditure, 1990-2003. Am Econ Rev 2007 97 : 438 43.
12. Grootendorst P, Pierard E, Shim MS. The life expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Mimeo, University of Toronto, 1997. Available from: http://individual.utoronto.ca/grootendorst/ pdf/Life-expectancy-gains-pharmaceutical-drugs.pdf [Accessed May 27, 2008 FR.
13. Stanley J, Szefler MD. The natural history of asthma and early intervention. J Allergy Clin Immunol 2002 9 : 549 53.
14. Canadian Lung Association. Medications for asthma. Available from: http://www.lung.ca/diseases-maladies/asthma-asthme/medications-medicaments/ index-e.php [Accessed May 27, 2008 JMM, Donnely LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005 330 : 1304 5.
15. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is a AMP kinase-dependant growth inhibitor for breast cancer cells. Cancer Res 2006 66 : 10269 73.
16. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. Circulation 2007 115 : 2761 88.
17. Coplay JB, Rosario R. Hypertension: a review and rational of treatment. Dis Mon 2005 51 : 548 614.
18. Faergeman O. Evolution of statin therapy: an ongoing story. Eur Heart J 2004 6 (A A3 7.